| scholarly article | Q13442814 |
| P2093 | author name string | Markus Luster | |
| Frederik A Verburg | |||
| Hanneke M Van Santen | |||
| P2860 | cites work | 2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism | Q22306402 |
| Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer | Q26829349 | ||
| Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer | Q28262641 | ||
| A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal | Q46880174 | ||
| The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma | Q47383808 | ||
| Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. | Q47793136 | ||
| Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer | Q47820717 | ||
| Strategies of radioiodine ablation in patients with low-risk thyroid cancer | Q47820730 | ||
| Success of the postoperative 131I therapy in young Belarusian patients with differentiated thyroid cancer after Chernobyl depends on the radiation absorbed dose to the blood and the thyroglobulin level | Q48699422 | ||
| Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience | Q50589541 | ||
| A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer | Q50597206 | ||
| Determinants of successful ablation and complete remission after total thyroidectomy and ¹³¹I therapy of paediatric differentiated thyroid cancer | Q51016692 | ||
| Quality-of-Life Changes in Patients with Thyroid Cancer After Withdrawal of Thyroid Hormone Therapy | Q51101509 | ||
| Pediatric thyroid carcinoma: incidence and outcomes in 1753 patients. | Q51134871 | ||
| The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer | Q51775246 | ||
| Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. | Q51782734 | ||
| 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer | Q30367068 | ||
| Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity | Q33381643 | ||
| 124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison | Q33749165 | ||
| Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy | Q33945566 | ||
| Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. | Q33995708 | ||
| Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer | Q34003472 | ||
| Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. | Q34255791 | ||
| Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule | Q34281129 | ||
| Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy | Q35163702 | ||
| The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study | Q36428409 | ||
| European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium | Q36489842 | ||
| The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy | Q36666417 | ||
| Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer. | Q36834614 | ||
| Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Associat | Q36837469 | ||
| Childhood thyroid cancer in Belarus, Russia, and Ukraine after Chernobyl and at present | Q36949787 | ||
| Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis | Q37004650 | ||
| Primary tumour diameter as a risk factor for advanced disease features of differentiated thyroid carcinoma | Q37344918 | ||
| Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis | Q37413348 | ||
| The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I. | Q37454471 | ||
| Prognosis of Differentiated Thyroid Cancer in Relation to Serum Thyrotropin and Thyroglobulin Antibody Status at Time of Diagnosis | Q37460181 | ||
| Sialoadenitis secondary to 131I therapy for well‐differentiated thyroid cancer | Q37804443 | ||
| The use of dosimetry in the treatment of differentiated thyroid cancer. | Q37850986 | ||
| German Association of Endocrine Surgeons practice guidelines for the surgical treatment of benign thyroid disease | Q37855681 | ||
| Is outcome of differentiated thyroid carcinoma influenced by tumor stage at diagnosis? | Q38301984 | ||
| Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma--a systematic review | Q38595673 | ||
| Individualized dosimetry in the management of metastatic differentiated thyroid cancer | Q39929649 | ||
| Normal Thyroid Function and the Risk of Atrial Fibrillation: the Rotterdam Study | Q41494127 | ||
| A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example | Q41505779 | ||
| Favourable course of disease after incomplete remission on 131I therapy in children with pulmonary metastases of papillary thyroid carcinoma: 10 years follow-up | Q41984826 | ||
| Low iodine diet in I-131 ablation of thyroid remnants. | Q42464889 | ||
| Impact of primary surgery on outcome in 300 patients with pathologic tumor-node-metastasis stage III papillary thyroid carcinoma treated at one institution from 1940 through 1989. | Q43583286 | ||
| Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients | Q43617702 | ||
| Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients | Q43882195 | ||
| Low-iodine diet in the treatment of differentiated thyroid cancer with radioactive iodine | Q44012923 | ||
| Two-week low iodine diet is necessary for adequate outpatient preparation for radioiodine rhTSH scanning in patients taking levothyroxine | Q44792492 | ||
| Twenty-Five Years After Chernobyl: Outcome of Radioiodine Treatment in Children and Adolescents With Very High-Risk Radiation-Induced Differentiated Thyroid Carcinoma | Q45147787 | ||
| Chromosome translocation frequency after radioiodine thyroid remnant ablation: a comparison between recombinant human thyrotropin stimulation and prolonged levothyroxine withdrawal. | Q45976222 | ||
| Reversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled study. | Q46677611 | ||
| Limited cytoprotective effects of amifostine in high-dose radioactive iodine 131-treated well-differentiated thyroid cancer patients: analysis of quantitative salivary scan | Q46701710 | ||
| Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration | Q46798198 | ||
| No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer | Q51788283 | ||
| Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma | Q51809324 | ||
| EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy | Q51956739 | ||
| I-131 SPECT/CT Elucidates Cryptic Findings on Planar Whole-Body Scans and Can Reduce Needless Therapy with I-131 in Post-Thyroidectomy Thyroid Cancer Patients | Q53196205 | ||
| Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer | Q53207435 | ||
| Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study | Q53263951 | ||
| The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging | Q53285396 | ||
| Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality | Q53308051 | ||
| Guidelines for radioiodine therapy of differentiated thyroid cancer | Q57482620 | ||
| Proceedings: Effect of a low iodine diet on 131-I therapy in follicular thyroid carcinomata | Q66935363 | ||
| Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer | Q71048700 | ||
| The impact of surgical technique on postoperative hypoparathyroidism in bilateral thyroid surgery: a multivariate analysis of 5846 consecutive patients | Q73046022 | ||
| Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach | Q73088067 | ||
| Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma | Q73138058 | ||
| A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer | Q73194183 | ||
| Salivary gland protection by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double-blind multi-arm trial | Q73886672 | ||
| Acute myeloid leukemia following prolonged iodine-131 therapy for metastatic thyroid carcinoma | Q74050328 | ||
| Multivariate analysis of prognostic factors for differentiated thyroid carcinoma in children | Q74204435 | ||
| Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer | Q77321980 | ||
| Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma | Q77321993 | ||
| Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry | Q77429537 | ||
| Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89 | Q79079499 | ||
| The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer | Q79248725 | ||
| The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer | Q79346777 | ||
| Risk factors of paralysis and functional outcome after recurrent laryngeal nerve monitoring in thyroid surgery | Q81290693 | ||
| Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? | Q81370175 | ||
| Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma | Q82384296 | ||
| Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008 | Q82576853 | ||
| Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal | Q83089295 | ||
| The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients | Q83139773 | ||
| Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007 | Q83206208 | ||
| A comparison of prognostic classification systems for differentiated thyroid carcinoma | Q84798543 | ||
| Approach to the patient: role of dosimetric RAI Rx in children with DTC | Q86479540 | ||
| Recurrent disease in juvenile differentiated thyroid carcinoma: prognostic factors, treatments, and outcomes | Q87658780 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | papillary thyroid cancer | Q2292945 |
| P304 | page(s) | 165-175 | |
| P577 | publication date | 2016-12-28 | |
| P1433 | published in | OncoTargets and Therapy | Q7092081 |
| P1476 | title | Pediatric papillary thyroid cancer: current management challenges | |
| P478 | volume | 10 |
| Q47093905 | RNA-sequencing investigation identifies an effective risk score generated by three novel lncRNAs for the survival of papillary thyroid cancer patients | cites work | P2860 |
Search more.